Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLYC
- Price
- 0.18
- Stock movement up
- +0.01 (4.25%)
- Company name
- GlycoMimetics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.85M
- Ent value
- 1.78M
- Price/Sales
- 1185.22
- Price/Book
- 0.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -13.11%
- 1 year return
- -93.32%
- 3 year return
- -45.73%
- 5 year return
- -38.45%
- 10 year return
- -31.55%
Last updated: 2025-04-09
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GLYC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1185.22 |
| Price to Book | 0.00 |
| EV to Sales | 178.24 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.48M |
| EPS (TTM) | -0.62 |
| FCF per share (TTM) | -425.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.00K |
| Gross profit (TTM) | -40.34K |
| Operating income (TTM) | -42.30M |
| Net income (TTM) | -39.74M |
| EPS (TTM) | -0.62 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -403.40% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.39M |
| Net receivables | 50.26K |
| Total current assets | 15.65M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 15.70B |
| Accounts payable | 581.79K |
| Short/Current long term debt | 262.13M |
| Total current liabilities | 4.32B |
| Total liabilities | 4.32M |
| Shareholder's equity | 15.69B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.40B |
| Capital expenditures (TTM) | 9.97M |
| Free cash flow (TTM) | -27.41B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -0.25% |
| Return on Assets | -0.25% |
| Return on Invested Capital | -0.25% |
| Cash Return on Invested Capital | -171.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.19 |
| Daily high | 0.20 |
| Daily low | 0.18 |
| Daily Volume | 398K |
| All-time high | 25.35 |
| 1y analyst estimate | 1.00 |
| Beta | 1.84 |
| EPS (TTM) | -0.62 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| GLYC | S&P500 | |
| Current price drop from All-time high | -99.28% | -19.00% |
| Highest price drop | -99.43% | -56.47% |
| Date of highest drop | 9 Oct 2024 | 9 Mar 2009 |
| Avg drop from high | -70.23% | -11.07% |
| Avg time to new high | 100 days | 12 days |
| Max time to new high | 1796 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
11.85M
Marketcap category
Small-cap
Description
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Employees
35
Investor relations
-
SEC filings
CEO
Rachel K. King
Country
USA
City
Rockville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page